Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali Volume 10 Issue 5 (2025)
OUTCOMES OF BLINATUMOMAB THE INITIAL PHASE OF CHEMOTHERAPY IN CHILDREN WITH B-CELL ALL
ИБРАГИМОВА Сапура Захидовна, КЛЕВЛЕЕВА Альбина Рустамовна, БАБАХАНОВА Наргиза Нусратуллаевна, РИЗАЕВА Феруза Абдулхамитовна, ЕРИМБЕТОВА Индира Оралбаевна, НИГМАТОВ Хамидхон Кобилович, АРИПОВА Назокат Баходировна
Abstract
This retrospective single‑center study (2020–2024) from the Pediatric Oncology Center in Tashkent evaluated the efficacy of incorporating blinatumomab (14‑day courses at 15 μg/m²/day, twice with a two‑month interval) into the ALL‑MB‑2015 protocol for children with B‑cell ALL who remained MRD‑positive post‑induction. All 25 patients achieved hematologic remission; MRD dropped from 12 % to 0.001 % after the first blinatumomab course, and remained negative after the second. Median follow‑up was 2.5 years. There were two late relapses (in standard‑ and intermediate‑risk groups), 4‑year EFS was 88.1 ± 3.7 %, and no deaths occurred. Adverse events (allergic reactions, neurotoxicity, hypoalbuminemia, cytopenias) were manageable.
острая лимфобластная лейкемия (ALL), блинатумомаб, минимальная остаточная болезнь (MRD), дети, протокол ALL MB 2015ALL, blinatumomab, minimal residual disease, childrenB-hujayrali OLL, blinatumomab, minimal qoldiq kasallik (MRD), bolalar, immunoterapiya
Metadata source: the journal's OAI-PMH archive · Sindex does not store the full text; it links to the source.